Favorable Media Coverage Somewhat Unlikely to Affect Luminex Corporation (LMNX) Share Price
Media stories about Luminex Corporation (NASDAQ:LMNX) have been trending positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Luminex Corporation earned a news impact score of 0.29 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 47.9493746673569 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- STERIS (STE) Q2 Earnings Miss & Revenues Beat, Margins Up (finance.yahoo.com)
- Omnicell's Higher Investments Drive Costs, Competition Rife (finance.yahoo.com)
- DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet (finance.yahoo.com)
- First Week of January 2018 Options Trading For Luminex (nasdaq.com)
- PerkinElmer (PKI) Beats Q3 Earnings, Updates '17 Guidance (finance.yahoo.com)
Shares of Luminex Corporation (NASDAQ LMNX) traded up $0.11 during mid-day trading on Friday, hitting $21.47. 246,338 shares of the stock were exchanged, compared to its average volume of 147,681. Luminex Corporation has a twelve month low of $17.68 and a twelve month high of $22.27. The company has a market capitalization of $945.84, a price-to-earnings ratio of 37.02, a PEG ratio of 3.30 and a beta of 0.18.
Luminex Corporation (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, October 30th. The medical instruments supplier reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.06. Luminex Corporation had a net margin of 9.52% and a return on equity of 6.01%. The firm had revenue of $74.14 million for the quarter, compared to analyst estimates of $74.38 million. During the same quarter in the previous year, the business posted $0.21 EPS. The firm’s revenue was up 4.1% compared to the same quarter last year. analysts forecast that Luminex Corporation will post 0.4 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, October 13th. Stockholders of record on Friday, September 22nd were paid a $0.06 dividend. The ex-dividend date was Thursday, September 21st. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.12%. Luminex Corporation’s dividend payout ratio (DPR) is presently 36.36%.
A number of brokerages have weighed in on LMNX. TheStreet raised shares of Luminex Corporation from a “c+” rating to a “b-” rating in a research note on Wednesday. BidaskClub lowered shares of Luminex Corporation from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $21.00 price target on shares of Luminex Corporation in a research note on Friday, October 20th. ValuEngine raised shares of Luminex Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Finally, Zacks Investment Research raised shares of Luminex Corporation from a “hold” rating to a “strong-buy” rating and set a $22.00 price target on the stock in a research note on Thursday, August 24th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $20.00.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/05/favorable-media-coverage-somewhat-unlikely-to-affect-luminex-corporation-lmnx-share-price.html.
In other news, Director Robert J. Cresci sold 19,631 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $18.98, for a total value of $372,596.38. Following the sale, the director now owns 260,358 shares in the company, valued at approximately $4,941,594.84. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 6.90% of the company’s stock.
About Luminex Corporation
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Stock Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related stocks with our FREE daily email newsletter.